Skip to main content
. 2026 Jun 17;22(3):270–278. doi: 10.4274/ejbh.galenos.2026.2025-9-15

Table 1. Comparison of clinical, laboratory, and treatment characteristics between recurrent and non-recurrent IGM patients.

Variable

IGM recurrence - no (n/%)

IGM recurrence - yes (n/%)

p-value

Total patients

70 (76.1%)

22 (23.9%)

-

Baseline characteristics

Age (mean ± SD)

36.10±9.63

36.10±9.63

>0.05

Time from symptom onset to diagnosis (months)

Not specified

Not specified

-

Clinical features

Presence of mass

70 (100%)

22 (100%)

-

Painful mass

50 (71.4%)

18 (81.8%)

-

Redness

32 (45.7%)

10 (45.4%)

-

Discharge

27 (38.5%)

9 (40.9%)

-

Fistula

5 (7.1%)

3 (13.6%)

-

Nipple retraction

10 (14.3%)

5 (22.7%)

-

Cellulitis

4 (5.7%)

2 (9.1%)

-

Erythema nodosum

6 (8.5%)

2 (9.1%)

-

Recurrent abscess

Not specified

Not specified

-

Unilateral lesion

61 (87.1%)

18 (81.8%)

-

Mass ≥5 cm on initial ultrasound

18 (26%)

8 (36%)

-

Laboratory findings

ESR >20 mm/h

21 (30%)

10 (45%)

0.023

CRP ≥5 mg/L

26 (37%)

8 (36%)

0.056

ACE >52 U/L

10 (14%)

4 (18%)

-

Prolactin (mean)

Not specified

Not specified

>0.05

Risk factors

Comorbidities

10 (14%)

5 (23%)

-

Stress factor

30 (43%)

9 (41%)

-

Oral contraceptive use

7 (10%)

2 (9%)

-

Menopause

3 (4.3%)

1 (4.5%)

-

Breast trauma

Not specified

Not specified

-

Treatment & follow-up

Initial steroid use

70 (100%)

22 (100%)

-

Initial methotrexate use

63 (90%)

22 (100%)

0.473

Initial azathioprine use

7 (10%)

0 (0%)

0.494

TNF-a inhibitor use

0 (0%)

17 (77.3%)

-

Methotrexate + cyclosporine

0 (0%)

5 (22.7%)

-

Combination therapy (any)

0 (0%)

22 (100%)

-

Follow-up status

Not specified

Not specified

-

ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; IGM: Idiopathic granulomatous mastitis; ACE: Angiotensin converting enzyme; TNF-a: Tumor necrosis factor alpha; SD: Standard deviation